Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

DOI： 10.1016/j.annonc.2024.08.2090

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

Peritoneal washing cytology (CY) in patients with pancreatic cancer is mainly used for staging; however, it may also be used to evaluate the intraperitoneal status to predict a more accurate prognosis. Here, we investigated the potential of deep learning of CY specimen images for predicting the 1-year prognosis of pancreatic cancer in CY-positive patients. CY specimens from 88 patients with prognostic information were retrospectively analyzed. CY specimens scanned by the whole slide imaging device were segmented and subjected to deep learning with a Vision Transformer (ViT) and a Convolutional Neural Network (CNN). The results indicated that ViT and CNN predicted the 1-year prognosis from scanned images with accuracies of 0.8056 and 0.8009 in the area under the curve of the receiver operating characteristic curves, respectively. Patients predicted to survive 1 year or more by ViT showed significantly longer survivals by Kaplan-Meier analyses. The cell nuclei found to have a negative prognostic impact by ViT appeared to be neutrophils. Our results indicate that AI-mediated analysis of CY specimens can successfully predict the 1-year prognosis of patients with pancreatic cancer positive for CY. Intraperitoneal neutrophils may be a novel prognostic marker and therapeutic target for CY-positive patients with pancreatic cancer.

DOI： 10.1038/s41598-024-67757-5

PubMed

researchmap

Other Link： https://www.nature.com/articles/s41598-024-67757-5

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

Abstract

Background

Prolonged laparoscopic nephroureterectomy (LNU) for upper tract urothelial cancer (UTUC) can increase the frequency of intravesical recurrence after surgery. Therefore, it is important for urological surgeons to have knowledge on preoperative risk factors for prolonged LNU. However, few studies have investigated the risk factors for prolonged LNU. We hypothesized that the quantity of perirenal fat affects the pneumoretroperitoneum time (PRT) of retroperitoneal LNU (rLNU). This study aimed to investigate the preoperative risk factors for prolonged PRT during rLNU.

Methods

We reviewed the data of 115 patients who underwent rLNU for UTUC between 2013 and 2021. The perirenal fat thickness (PFT) observed on preoperative computed tomography (CT) images was used to evaluate the perinephric fat quantity. Preoperative risk factors for PRT during rLNU were analyzed using logistic regression models. The cutoff value for PRT was determined based on the median time.The cutoff values for fat-related factors influencing PRT were defined according to receiver operating characteristic curve analysis.

Results

The median PRT for rLNU was 182 min (interquartile range, 155–230 min). The cutoff values of posterior, lateral, and anterior PFTs were 15 mm, 24 mm, and 6 mm, respectively. Multivariate analysis revealed that a posterior PFT ≥ 15 mm (odds ratio [OR], 2.72; 95% confidence interval, 1.04–7.08; p = 0.0410) was an independent risk factor for prolonged PRT.

Conclusions

Thick posterior PFT is a preoperative risk factor for prolonged PRT during rLNU. For patients with UTUC and thick posterior PFT, surgeons should develop optimal surgical strategies, including the selecting an expert surgeon as a primary surgeon and the selecting transperitoneal approach to surgery or open surgery.

DOI： 10.1186/s12894-024-01538-0

PubMed

researchmap

Other Link： https://link.springer.com/article/10.1186/s12894-024-01538-0/fulltext.html

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Index tumors are the most aggressive tumors of the prostate. However, their clinical significance remains unclear. This study aimed to assess the incidence of index tumor location according to the zonal origin and whether these locations affect the prognosis after radical prostatectomy in patients with negative surgical margins. METHODS: This single-centered, retrospective study evaluated 1,109 consecutive patients who underwent radical prostatectomies. An index tumor was defined as the largest tumor in the prostate gland. We detected these locations based on McNeal's zonal origin using whole-mount sections. Biochemical recurrence (BCR) free survival curves were generated using the Kaplan-Meier method. Univariate and multivariate analyses using the Cox proportional hazards model were performed to determine the predictive factors for early BCR (within 1-year). RESULTS: A total of 621 patients with negative surgical margins who did not receive adjuvant therapy were included in this study. The index tumor were located in the transitional zone in 191 patients (30.8%), the peripheral zone in 399 patients (64.3%), and the central zone in 31 patients (5.0%). In total, 22 of 621 patients (3.5%) experienced early BCR and 70 patients (11.2%) experienced overall BCR at a median follow-up of 61.7 months. According to the index tumor location, the early BCR-free rates were 99.5%, 95.7 %, and 83.3% in the transitional, peripheral, and central zones, respectively. On multivariate analysis, the index tumor in the central zone was an independent predictor of early BCR with negative surgical margins following radical prostatectomy, followed by prostatectomy pathological grade, index tumor in the peripheral zone, and high prostate-specific antigen level. CONCLUSIONS: We assessed the significance of index tumor location in patients with negative surgical margins following radical prostatectomy. Index tumors located in the central zone, although infrequent, were the strongest predictive factors for early BCR. Our results may allow urologists and patients to reconsider the therapeutic strategies for prostate cancer.

DOI： 10.1186/s12894-024-01499-4

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

In patients with high-risk prostate cancer (HRPC) after radical prostatectomy (RP), biochemical recurrence (BCR) increases the risk of distant metastasis. Accordingly, additional prognostic biomarkers are required to identify the subpopulation of patients with HRPC who develop clinical recurrence (CR) after BCR. The objective of this study was to identify biomarkers in formalin-fixed paraffin-embedded (FFPE) RP samples that are prognostic for CR in patients with HRPC who experience BCR after RP (post-RP BCR). First, we performed a preliminary RNA sequencing analysis to comprehensively profile RNA expression in FFPE RP samples obtained from patients with HRPC who developed CR after post-RP BCR and found that many snRNAs were very abundant in preserved FFPE samples. Subsequently, we used quantitative polymerase chain reaction (qPCR) to compare the expression levels of highly abundant snRNAs in FFPE RP samples from patients with HRPC with and without CR after post-RP BCR (21 CR patients and 46 non-CR patients who had more than 5 years of follow-up after BCR). The qPCR analysis revealed that the expression levels of snRNA RNU1-1/1-2 and RNU4-1 were significantly higher in patients with CR than in patients without CR. These snRNAs were significantly correlated with clinical recurrence-free survival (RFS) in patients with HRPC who experienced post-RP BCR. Furthermore, snRNA RNU1-1/1-2 could serve as an independent prognostic factor for clinical RFS in post-RP BCR of HRPC cases where known prognostic factors (e.g., Gleason score) cannot distinguish between CR and non-CR patients. Our findings provide new insights into the involvement of snRNAs in prostate cancer progression.

DOI： 10.3390/cancers16091757

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: The Vesical Imaging Reporting and Data System (VI-RADS) is widely used for predicting muscle-invasive bladder cancer (MIBC). This study aimed to determine the clinicopathological significance of the VI-RADS ≧4 (VI≧4) group. METHODS: Patients who underwent transurethral resections of bladder tumors during the study period and preoperative magnetic resonance imaging were considered. The patients were pathologically diagnosed with urothelial carcinoma (UC). We first compared the results of patients with VI-RADS scores of 3 and 4 to determine the cut-off score for MIBC; thereafter, the patients were divided into the VI≧4 and VI-RADS ≦3 (VI≦3) groups using VI-RADS. The clinicopathological significance of the VI≧4 group was examined retrospectively by comparing the characteristics of each group. RESULTS: In total, 121 cases were examined, of which 28 were pathologically diagnosed with MIBC. Of the 28 MIBC cases, three (10.7%) had a VI-RADS score of ≦3, and 25 (89.3%) had a VI-RADS score of ≧4. Of the 93 NMIBC cases, 86 (92.5%) had a VI-RADS score of ≦3, and seven (7.5%) had a VI-RADS score of ≧4. The diagnostic performance of the VI-RADS with a cut-off score of 4 was 89.3% for sensitivity, 92.5% for specificity, and an area under the curve (AUC) of 0.91. Contrastingly, for a cut-off score of 3, the sensitivity was 89.3%, specificity was 62.0%, and AUC was 0.72. A VI-RADS score of ≥ 4 could predict MIBC. In the VI≧4 group, 30 of 32 (93.8%) patients had high-grade tumors. The VI≧4 group had significantly more high-grade bladder cancers than the VI≦3 group (p < 0.001 OR = 31.77 95%CI:8.47-1119.07). In addition, the VI≧4 group had more tumor necrosis (VI≧4 vs VI≦3, p < 0.001 OR = 7.46 95%CI:2.61-21.34) and more UC variant cases (VI≧4 vs VI≦3, p = 0.034 OR = 3.28 95%CI:1.05-10.25) than the VI≦3 group. CONCLUSIONS: This study suggests that VI-RADS has a high diagnostic performance in predicting MIBC and that VI-RADS could diagnose high-grade tumors, necrosis, and UC variants.

DOI： 10.1186/s12894-024-01452-5

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Ovid Technologies (Wolters Kluwer Health)  

Objectives

Pancreatic ductal adenocarcinoma is an intractable disease with frequent recurrence after resection and adjuvant therapy. The present study aimed to clarify whether artificial intelligence–assisted analysis of histopathological images can predict recurrence in patients with pancreatic ductal adenocarcinoma who underwent resection and adjuvant chemotherapy with tegafur/5-chloro-2,4-dihydroxypyridine/potassium oxonate.

Materials and Methods

Eighty-nine patients were enrolled in the study. Machine-learning algorithms were applied to 10-billion-scale pixel data of whole-slide histopathological images to generate key features using multiple deep autoencoders. Areas under the curve were calculated from receiver operating characteristic curves using a support vector machine with key features alone and by combining with clinical data (age and carbohydrate antigen 19-9 and carcinoembryonic antigen levels) for predicting recurrence. Supervised learning with pathological annotations was conducted to determine the significant features for predicting recurrence.

Results

Areas under the curves obtained were 0.73 (95% confidence interval, 0.59–0.87) by the histopathological data analysis and 0.84 (95% confidence interval, 0.73–0.94) by the combinatorial analysis of histopathological data and clinical data. Supervised learning model demonstrated that poor tumor differentiation was significantly associated with recurrence.

Conclusions

Results indicate that machine learning with the integration of artificial intelligence–driven evaluation of histopathological images and conventional clinical data provides relevant prognostic information for patients with pancreatic ductal adenocarcinoma.

DOI： 10.1097/MPA.0000000000002289

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

This study presents the enfortumab vedotin (EV) treatment analysis at our institution. We retrospectively analyzed patients with metastatic urothelial cancer (mUC) treated with EV between January 2021 and October 2023. EV was administered at 1.25 mg/kg on days 1, 8, and 15 in a 28-day cycle. Whole-body computed tomography scans were performed to assess the treatment response. Patient characteristics, treatment histories, response rates, progression-free survival, and adverse events were evaluated. Response rates were determined, and adverse events were recorded. Among the 20 patients, 70% were male and 65% had bladder tumors. Most patients had lung (65%) or lymph node (65%) metastases. The median follow-up was 11.2 months, with 45% of the patients succumbing to the disease. The overall response rate was 55%. The median progression-free and median overall survivals were 10.5 and 12.9 months, respectively. Severe adverse events occurred in 35% of patients. In this real-world study, EV demonstrated promising efficacy and manageable safety profiles in Japanese patients with mUC. The study's results were consistent with previous clinical trials, although a longer follow-up was required. Our findings support EV use as a treatment option for patients with mUC who exhibit disease progression after platinum-based chemotherapy and immune-checkpoint inhibitor therapy.

DOI： 10.3390/curroncol31020056

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Medical Association of Nippon Medical School  

BACKGROUND: This study aimed to investigate the preoperative risk factors for prolonged operating time in retroperitoneoscopic radical nephrectomy (RRN) for renal cell carcinoma (RCC). METHODS: We retrospectively reviewed patients treated for RRN between January 2015 and December 2021. Clinical data, including radiological findings such as visceral fat area (VFA), subcutaneous fat area (SFA), and posterior perirenal fat thickness (PFT) were collected. The operating time for RRN was analyzed using univariate and multivariate logistic regression analyses. RESULTS: A total of 79 patients were included. The median age was 66 (range: 28-88) years and 48 (60.8%) had right-sided tumors. The median tumor size was 52 (range: 12-100) mm. Median BMI, VFA, SFA, and posterior PFT were 22.9 (range: 16.3-42.2) kg/m2, 102 (range: 14-290) cm2, 124 (range: 33-530) cm2, and 6 (range: 1-35) mm. The median operating time was 248 (range: 140-458) min. Univariate logistic regression analyses revealed that a right tumor (p=0.046), tumor size >7 cm (p=0.010), and posterior PFT >25 mm (p=0.006) were preoperative risk factors for prolonged operating time in RRN. Multivariate logistic regression analyses revealed that a posterior PFT of >25 mm was an independent preoperative risk factor for prolonged operating time for RRN (p=0.008, OR: 7.29, 95% CI: 1.69-31.5). CONCLUSIONS: A posterior PFT >25 mm was an independent preoperative risk factor for the operating time of RRN. In RRN, for patients with a posterior PFT >25 mm, surgeons should develop surgical strategies, including the selection of a transperitoneal approach to surgery, to avoid prolonging the operating time.

DOI： 10.1272/jnms.JNMS.2024_91-407

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Renal abscesses require prompt diagnosis and appropriate intervention, as they can be life-threatening. However, diagnosis based solely on clinical findings is often challenging. We present the case of a 69-year-old woman with left renal masses on follow-up computed tomography (CT) after surgery for pT2aN0M0 lung carcinosarcoma. The masses were localized only in the left kidney without suspected metastatic lesions at other sites. The patient was referred to our department for further evaluation and treatment under a diagnosis of suspected metastatic lung carcinosarcoma of the left kidney. On enhanced CT, the left renal masses, the largest of which had a diameter of 40×36 mm had thick irregular walls gradually enhanced by the contrast media and an internal low-attenuation area. The masses showed heterogeneous signal intensity with a pseudocapsule on T2-weighted magnetic resonance imaging. Clinical symptoms such as fever or costovertebral angle tenderness were absent, and blood and urine tests were not sufficiently inflammatory to suggest a renal abscess. Histopathological findings on CT-guided renal biopsy revealed only inflammatory tissue and no tumor cells. However, because lung carcinosarcoma metastatic nodules could not be ruled out, laparoscopic left nephrectomy was performed for a definitive diagnosis and curative intent. The pathological diagnosis was renal abscess without malignant lesions. Here, we present a case of renal abscess mimicking metastatic lesions in a patient with lung carcinosarcoma. Accurately differentiating renal abscesses from metastatic renal tumors before treatment is often difficult. Renal abscess diagnosis should be considered through a comprehensive evaluation of the clinical findings of individual cases.

DOI： 10.1272/jnms.JNMS.2024_91-609

Scopus

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

Introduction

We report a rare case of marked rectal stenosis due to Douglas' pouch metastasis of renal pelvic urothelial carcinoma successfully treated with enfortumab vedotin.

Case presentation

A 77‐year‐old female presented with difficulty in defecation and abdominal distension. She had received two courses of cisplatin plus gemcitabine followed by four courses of maintenance avelumab for postoperative lymph node metastasis of renal pelvic urothelial carcinoma. KL‐6 levels were elevated, and a computed tomography scan revealed an irregularly shaped large mass occupying Douglas' pouch, with marked rectal stenosis. Metastatic urothelial carcinoma was pathologically diagnosed, and enfortumab vedotin was initiated after colostomy. After 12 courses of enfortumab vedotin, metastatic lesions showed marked shrinkage and KL‐6 levels decreased.

Conclusion

Enfortumab vedotin elicited a remarkable response in treating rectal stenosis due to metastasis of renal pelvic urothelial carcinoma in Douglas' pouch. Furthermore, serum KL‐6 levels were correlated with the severity of metastatic urothelial carcinoma.

DOI： 10.1002/iju5.12645

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: To investigate the impact of Perirenal fat stranding (PRFS) on progression after radical nephroureterectomy (RNU) for renal pelvic urothelial carcinoma (RPUC) without hydronephrosis and to reveal the pathological findings of PRFS. METHODS: Clinicopathological data, including computed tomography (CT) findings of the ipsilateral PRFS, were collected from the medical records of 56 patients treated with RNU for RPUC without hydronephrosis between 2011 and 2021 at our institution. PRFS on CT was classified as either low or high PRFS. The impact of PRFS on progression-free survival (PFS) after RNU was analyzed using the Kaplan-Meier method and log-rank test. In addition, specimens including sufficient perirenal fat from patients with low and with high PRFS were pathologically analyzed. Immunohistochemical analysis of CD68, CD163, CD3, and CD20 was also performed. RESULTS: Of the 56 patients, 31(55.4%) and 25 (44.6%) patients were classified as having low and high PRFS, respectively. Within a median follow-up of 40.6 months postoperatively, 11 (19.6%) patients showed disease progression. The Kaplan-Meier method and log-rank test revealed that patients with high PRFS had significantly lower PFS rates than those with low PRFS (3-year PFS 69.8% vs 93.3%; p = 0.0393). Pathological analysis revealed that high PRFS specimens (n = 3 patients) contained more fibrous strictures in perirenal fat than low PRFS specimens (n = 3 patients). In addition, M2 macrophages (CD163 +) infiltrating fibrous tissue in perirenal area were observed in all patients with high PRFS group. CONCLUSIONS: PRFS of RPUC without hydronephrosis consists of collagenous fibers with M2 macrophages. The presence of ipsilateral high PRFS might be a preoperative risk factor for progression after RNU for RPUC patients without hydronephrosis. Prospective studies with large cohorts are required in the future.

DOI： 10.1007/s12672-023-00741-z

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: The optimal treatment modality for locally advanced prostate cancer has not been established. Radiotherapy, hormonal therapy, and combinations of treatments are the main strategies, although the feasibility of radical prostatectomy as a first-line therapy needs to be considered. This retrospective study evaluated the long-term oncological outcome of high-risk prostate cancer treated surgically, using pathological results of the extracted specimen. The relationship between the number of risk factors and the long-term outcome was specifically analyzed. METHODS: High-risk prostate cancer patients who underwent laparoscopic radical prostatectomy at Nippon Medical School from 2000 to 2012 without neoadjuvant therapy of any kind were identified. Risk factors were prostate-specific antigen (PSA) ≥20 ng/ml, pathological ≥T3, and pathological Gleason Score ≥8. Biological failure was defined as PSA ≥0.2 ng/ml. RESULTS: A total of 222 men were identified. One patient had positive lymph node status, and there was a significant difference in surgical margin positivity (52 men, 68.4% vs 56 men 38.4%) between patients with and without biochemical failure. For patients meeting the high risk criteria with a follow-up of up to 133 months, the biochemical recurrence (BCR) -free survival rates at 5 and 10 years were 62.8% and 58.4%, respectively, with a mean time to BCR of 14.0 months. BCR-free survival rates at 5 and 10-year were 73.6% and 71.4%, respectively, with 1 risk factor, 48.7% and 34.6%, respectively, with 2 factors, and 34.5% and 34.5%, respectively, with 3 factors. A single risk factor group had a significantly better outcome than the group with multiple risk factors. The overall survival rate at 5 and 10 years were 94.6% and 93.7%, and the cancer-specific survival rate was 100% at both 5 and 10 years. CONCLUSIONS: Reasonable long-term oncological outcomes can be achieved by surgical treatment for high-risk prostate cancer. The group with 1 risk factor had a significantly better BCR-free rate than the multiple risk factor group.

DOI： 10.1272/jnms.JNMS.2023_90-210

PubMed

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

INTRODUCTION: We encountered an extremely rare case of a vesicocutaneous fistula due to vesical diverticulitis with stones. CASE PRESENTATION: A 78-year-old male patient presented to our department with complaints of suppurative discharge in the suprapubic area. Computed tomography revealed an enlarged prostate, a vesical diverticulum with stones located on the ventral side, and an aberrant connection between the anterior bladder wall and the external surface of the skin. The patient was diagnosed with a vesicocutaneous fistula due to vesical diverticulitis and was successfully treated with a multidisciplinary approach including vesical diverticulectomy with stone removal and nonviable tissue debridement. The patient continues to receive regular outpatient follow-ups with urinary catheter changes. CONCLUSION: Vesicocutaneous fistulas due to vesical diverticulitis with stones are extremely rare. We should be aware that a vesical diverticulum with stones located on the ventral side might pose a high-risk factor for the formation of a vesicocutaneous fistula in elderly patients.

DOI： 10.1002/iju5.12546

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

The case presented is of a 47-year-old patient with an extravesical pedunculated bladder leiomyoma, which was difficult to distinguish from a retroperitoneal tumor. Preoperatively, it was suspected to be a retroperitoneal tumor and a laparotomy with tumor resection was performed. lntraoperatively, the bladder and tumor were connected by a cord-like tissue. A retrospective review of preoperative images revealed that cord-like tissue, identified intraoperatively, was also present. Bladder leiomyomas can grow as extravesical pedunculated tumors. Therefore, when the continuity between the bladder and tumor is only a cord-like object, the finding ofcontinuity is useful to diagnose with bladder leiomyoma. J. Med. Invest. 70 : 513-515, August, 2023.

DOI： 10.2152/jmi.70.513

PubMed

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: Human papillomavirus subtypes are predictive indicators of cervical intraepithelial neoplasia (CIN) progression. While colposcopy is also an essential part of cervical cancer prevention, its accuracy and reproducibility are limited because of subjective evaluation. This study aimed to develop an artificial intelligence (AI) algorithm that can accurately detect the optimal lesion associated with prognosis using colposcopic images of CIN2 patients by utilizing objective AI diagnosis. METHODS: We identified colposcopic findings associated with the prognosis of patients with CIN2. We developed a convolutional neural network that can automatically detect the rate of high-grade lesions in the uterovaginal area in 12 segments. We finally evaluated the detection accuracy of our AI algorithm compared with the scores by multiple gynecologic oncologists. RESULTS: High-grade lesion occupancy in the uterovaginal area detected by senior colposcopists was significantly correlated with the prognosis of patients with CIN2. The detection rate for high-grade lesions in 12 segments of the uterovaginal area by the AI system was 62.1% for recall, and the overall correct response rate was 89.7%. Moreover, the percentage of high-grade lesions detected by the AI system was significantly correlated with the rate detected by multiple gynecologic senior oncologists (r=0.61). CONCLUSION: Our novel AI algorithm can accurately determine high-grade lesions associated with prognosis on colposcopic images, and these results provide an insight into the additional utility of colposcopy for the management of patients with CIN2.

DOI： 10.3802/jgo.2022.33.e57

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: We evaluated whether the efficacy and safety of transurethral enucleation with bipolar energy (TUEB) is affected by prostate volume (PV) in the treatment of benign prostatic hyperplasia (BPH). METHODS: We retrospectively evaluated 180 patients with symptomatic BPH who underwent TUEB between 2008 and 2015. Efficacy was assessed by perioperative changes in the international prostate symptom score (IPSS), Quality of Life Score (QOLS), maximum flow rate on uroflowmetry (Qmax), and serum prostate-specific antigen level (PSA), which were recorded at 3 months postoperative. Safety was assessed by perioperative incidence of adverse events (AEs). AEs were recorded up to 2 years after surgery. Patients were divided into two groups based on PV: standard group (SG), PV < 80 mL, and large group (LG), PV ≥ 80 mL. RESULTS: A total of 132 (73%) patients were grouped in the SG, whereas 48 (27%) were grouped in the LG. No significant differences were observed in the preoperative parameters of age, IPSS, and QOLS between the two groups. However, the LG had a significantly larger PV and higher serum PSA levels. Regarding surgical outcomes, postoperative changes in IPSS, QOLS, Qmax, serum PSA, serum sodium, and hemoglobin levels did not differ significantly between the groups. However, the LG demonstrated a significantly longer operative time and heavier specimen weight. The rates of early complications, including hyponatremia, and blood transfusion, and late complications after surgery did not differ between the groups. CONCLUSION: This study demonstrated the safety and efficacy of TUEB for BPH therapy regardless of PV.

DOI： 10.1272/jnms.JNMS.2022_89-411

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Medical Association of Nippon Medical School  

Postoperative rhabdomyolysis is a rare but potentially fatal surgical complication. We experienced a case of rhabdomyolysis after laparoscopic radical nephrectomy (LRN). Right renal carcinoma was diagnosed in a 31-year-old woman with a body mass index of 28.5 kg/m2. She underwent right retroperitoneal LRN in the lateral decubitus position. The operating time was approximately 5 hours. Immediately after surgery, she reported pain in the left buttock, and reddish discoloration of the urine was observed. On the basis of these symptoms, an elevated serum creatine kinase level, and computed tomography findings, we diagnosed rhabdomyolysis of the left gluteal muscle secondary to its intraoperative compression caused by prolonged placement in a fixed position. She was treated with hydration therapy and discharged 6 days postoperatively. Prolonged surgery, obesity, and placement in the lateral decubitus position are risk factors for postoperative rhabdomyolysis. Surgeons should attempt to reduce operating time for LRN when obese patients are placed in the lateral decubitus position.

DOI： 10.1272/jnms.JNMS.2022_89-208

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

Abstract

Background

Active surveillance (AS) is one of the treatment methods for patients with small renal masses (SRMs; &lt; 4 cm), including renal cell carcinomas (RCCs). However, some small RCCs may exhibit aggressive neoplastic behaviors and metastasize. Little is known about imaging biomarkers capable of identifying potentially aggressive small RCCs. Contrast-enhanced computed tomography (CECT) often detects collateral vessels arising from neoplastic angiogenesis in RCCs. Therefore, this study aimed to evaluate the association between SRM differential diagnoses and prognoses, and the detection of collateral vessels using CECT.

Methods

A total of 130 consecutive patients with pathologically confirmed non-metastatic SRMs (fat-poor angiomyolipomas [fpAMLs; n = 7] and RCCs [n = 123]) were retrospectively enrolled. Between 2011 and 2019, SRM diagnoses in these patients were confirmed after biopsy or surgical resection. All RCCs were surgically resected. Regardless of diameter, a collateral vessel (CV) was defined as any blood vessel connecting the tumor from around the kidney using CECT. First, we analyzed the role of CV-detection in differentiating between fpAML and RCC. Then, we evaluated the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of RCC diagnosis based on CV-detection using CECT. We also assessed the prognostic value of CV-detection using the Fisher exact test, and Kaplan-Meier method and the log-rank test.

Results

The sensitivity, specificity, PPV, NPV, and accuracy of CV-detection for the diagnosis of small RCCs was 48.5, 45.5, 100, 100, and 9.5% respectively. Five of 123 (4.1%) patients with RCC experienced recurrence. CV-detection using CECT was the only significant factor associated with recurrence (p = 0.0177). Recurrence-free survival (RFS) was significantly lower in patients with CV compared with in those without CV (5-year RFS 92.4% versus 100%, respectively; p = 0.005). In addition, critical review of the CT images revealed the CVs to be continuous with the venous vessels around the kidney.

Conclusions

The detection of CVs using CECT is useful for differentiating between small fpAMLs and RCCs. CV-detection may also be applied as a predictive parameter for small RCCs prone to recurrence after surgical resection. Moreover, AS could be suitable for small RCCs without CVs.

DOI： 10.1186/s12885-022-09971-w

PubMed

researchmap

Other Link： https://link.springer.com/article/10.1186/s12885-022-09971-w/fulltext.html

Language：Japanese   Publisher：(一社)腎癌研究会  

J-GLOBAL

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Accurate prostate cancer screening is imperative for reducing the risk of cancer death. Ultrasound imaging, although easy, tends to have low resolution and high inter-observer variability. Here, we show that our integrated machine learning approach enabled the detection of pathological high-grade cancer by the ultrasound procedure. Our study included 772 consecutive patients and 2899 prostate ultrasound images obtained at the Nippon Medical School Hospital. We applied machine learning analyses using ultrasound imaging data and clinical data to detect high-grade prostate cancer. The area under the curve (AUC) using clinical data was 0.691. On the other hand, the AUC when using clinical data and ultrasound imaging data was 0.835 (p = 0.007). Our data-driven ultrasound approach offers an efficient tool to triage patients with high-grade prostate cancers and expands the possibility of ultrasound imaging for the prostate cancer detection pathway.

DOI： 10.1038/s41598-022-04951-3

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Robot-assisted laparoscopic prostatectomy (RALP) for prostate cancer was introduced in 2000 and rapidly gained popularity. The Da Vinci Surgical System? can ensure improved local control of cancer and fewer perioperative complications. However, RALP is performed in the steep-Trendelenburg position (a combination of lithotomy and head-down tilt position/Lloyd-Davies position) to obtain a good surgical view, and as a result, well leg compartment syndrome (WLCS) can become a serious complication of RALP. Here, we report a case of WLCS after RALP. A 75-year-old man underwent surgery for prostate cancer and immediately complained of pain and numbness after surgery. The pressure of the four leg compartments increased. Ultimately, we diagnosed the patient with WLCS in his right leg, and an emergency fasciotomy was performed. He completely recovered with no permanent disability and was discharged one month after rehabilitation. Although WLCS after RALP is a rare and severe complication, the patient recovered completely with early diagnosis and intervention. Measuring the compartment pressure is useful when the patient is drowsy immediately after recovery from anesthesia. Preventing WLCS requires identifying this condition as a potential complication of RALP and all urologic surgeries performed in the lithotomy position. J. Med. Invest. 69 : 145-147, February, 2022.

DOI： 10.2152/jmi.69.145

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: One of the major concerns of patients with upper tract urothelial carcinoma (UTUC) treated with nephroureterectomy is intravesical recurrence (IVR). The purpose of the present study was to investigate the predictive risk factors for IVR after retroperitoneoscopic nephroureterectomy (RNU) for UTUC. METHODS: Clinicopathological and surgical information were collected from the medical records of 73 patients treated with RNU for non-metastatic UTUC, without a history of or concomitant bladder cancer. The association between IVR after RNU and clinicopathological and surgery-related factors, including preoperative urine cytology and pneumoretroperitoneum time, was analyzed using the Fisher exact test. RESULTS: During the median follow-up time of 39.1 months, 18 (24.7%) patients had subsequent IVR after RNU. The 1- and 3-year IVR-free survival rates were 85.9% and 76.5%, respectively. The Fisher exact test revealed that prolonged pneumoretroperitoneum time of ≥ 210 min was a risk factor for IVR in 1 year after RNU (p = 0.0358) and positive urine cytology was a risk factor for IVR in 3 years after RNU (p = 0.0352). CONCLUSIONS: In UTUC, the occurrences of IVR in 1 and 3 years after RNU are highly probable when the pneumoretroperitoneum time is prolonged (≥ 210 min) and in patients with positive urine cytology, respectively. Strict follow-up after RNU is more probable recommended for these patients.

DOI： 10.1186/s12894-021-00932-2

PubMed

researchmap

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：University of Tokushima Faculty of Medicine  

Hem-o-lok clips are commonly used for renal artery ligation in laparoscopic renal surgery. However, failure of the renal artery ligation clips is potentially fatal. A 61-year-old man underwent hand-assisted laparoscopic nephroureterectomy using a retroperitoneal approach for left ureteral carcinoma. One hour postoperatively, he was diagnosed with hemorrhagic shock. An immediate laparotomy revealed two closed, undamaged Hem-o-lok clips around the left renal artery. Pulsatile bleeding was observed, and the renal artery was immediately ligated with non-absorbable thread. We determined that the failure of the Hem-o-lok clips on the renal artery was caused by the lack of space between the two Hem-o-lok clips and the distal renal artery cuff beyond the distal clip. To prevent a potentially fatal failure of the renal artery ligation clips, one should maintain a sufficient space between the Hem-o-lok clips and an adequate distal renal artery cuff beyond the distal clip. J. Med. Invest. 68 : 393-395, August, 2021.

DOI： 10.2152/jmi.68.393

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: While high body mass index (BMI) and visceral obesity are reportedly associated with a prolonged duration of laparoscopic radical nephrectomy (LRN) via the transperitoneal approach, factors that might prolong the retroperitoneal approach remain unknown. We therefore investigated factors associated with prolonged LRN using a retroperitoneal approach applied by non-expert surgeons. METHODS: We defined surgeons who were not certified to perform laparoscopic surgery by the Japanese Society of Endourology as non-experts. We retrospectively reviewed the medical records of 59 consecutive patients with renal cell carcinoma treated with LRN using the retroperitoneal approach by non-experts at our hospital between 2014 and 2019. Relationships between surgical duration and age, sex, body mass index, visceral fat area (VFA) and subcutaneous fat area (SFA), laterality and location of the tumor, length of major tumor axis (tumor length), clinical T stage, ipsilateral adrenalectomy and specimen weight were analyzed using Spearman rank correlation coefficients. RESULTS: The surgical duration positively correlated with ipsilateral adrenalectomy (rs = 0.3162, p = 0.0147) and specimen weight (rs = 0.3103, p = 0.0168), but not with BMI (rs = 0.2016, p = 0.1257) or VFA (rs = 0.0185, p = 0.8894). CONCLUSIONS: Factors associated with prolonged LRN via the retroperitoneal approach implemented by non-expert surgeons are ipsilateral adrenalectomy and specimen weight.

DOI： 10.1272/jnms.JNMS.2021_88-302

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Introduction: We encountered an extremely rare case of a nephrostomy catheter entering the right renal vein during an exchange procedure. Case presentation: An 80-year-old man underwent radical cystectomy. Urinary diversion was achieved through right percutaneous nephrostomy. After the 15th nephrostomy catheter exchange, the patient bled heavily from the catheter. We clamped the catheter immediately, and the patient became hemodynamically stable. Emergency angiography showed the nephrostomy catheter entering the renal vein from outside the renal pelvis. Under fluoroscopy, we pulled the catheter until its tip was located in the previous penetration site of the renal pelvic wall and inserted the catheter over the guidewire into the renal pelvis. Conclusions: Herein, we report an extremely rare case of a nephrostomy catheter inserted into the right renal vein during an exchange procedure. Inserting a nephrostomy catheter in the appropriate position and performing exchange under imaging guidance techniques could help clinicians avoid severe complications.

DOI： 10.1002/iju5.12276

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Transrectal ultrasonography (TRUS)-guided prostate biopsy is the conventional method of diagnosing prostate cancer. TRUS-guided prostate biopsy can occasionally be associated with severe complications. Here, we report the first case of a prostate abscess with aneurysms and spondylodiscitis as a complication of TRUS-guided prostate biopsy, and we review the relevant literature. CASE PRESENTATION: A 78-year-old man presented with back pain, sepsis, and prostate abscesses. Twenty days after TRUS-guided prostate biopsy, he was found to have a 20-mm diameter abdominal aortic aneurysm that expanded to 28.2 mm in the space of a week, despite antibiotic therapy. Therefore, he underwent transurethral resection of the prostate to control prostatic abscesses. Although his aneurysm decreased to 23 mm in size after surgery, he continued to experience back pain. He was diagnosed as having pyogenic spondylitis and this was managed using a lumbar corset. Sixty-four days after the prostate biopsy, the aneurysm had re-expanded to 30 mm; therefore, we performed endovascular aneurysm repair (EVAR) using a microcore stent graft 82 days after the biopsy. Four days after the EVAR, the patient developed acute cholecystitis, and he underwent endoscopic retrograde biliary drainage. One hundred and sixty days after the prostate biopsy, all the complications had improved, and he was discharged. A literature review identified a further six cases of spondylodiscitis that had occurred after transrectal ultrasound-guided prostate biopsy. CONCLUSIONS: We have reported the first case of a complication of TRUS-guided prostate biopsy that involved prostatic abscesses, aneurysms, and spondylodiscitis. Although such complications are uncommon, clinicians should be aware of the potential for such severe complications of this procedure to develop.

DOI： 10.1186/s12894-021-00780-0

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Laparoscopic radical nephrectomy (LRN) is the standard surgical treatment for localized renal cell carcinoma. LRN can be performed using a transperitoneal or retroperitoneal approach. We report a case of a complication specific to the retroperitoneal approach. A 63-year-old woman with localized right renal cell carcinoma was treated with retroperitoneal LRN. During placement of the first port, tumor vessels were damaged by a balloon dilator. Massive hemorrhage from the retroperitoneal cavity required conversion to retroperitoneal laparotomy to stop the bleeding. When laparotomy was performed, active bleeding had already ceased. The bleeding was caused by damage to the tumor vessels from the balloon dilator. Subsequent nephrectomy was performed without other complications. This case suggests that the transperitoneal approach is safer than the retroperitoneal approach when a tumor is located laterally and contains many tumor vessels.

DOI： 10.1272/jnms.JNMS.2021_88-412

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Plasmacytoid urothelial carcinoma (PUC) of the urinary bladder is a variant of urothelial carcinoma that carries a poor prognosis. The epithelial-mesenchymal transition (EMT) has been demonstrated to contribute to tumor progression. As the cause of the increased aggressiveness of PUC is unknown, we investigated PUC and EMT-related marker expression. METHODS: A total of 633 bladder carcinoma cases diagnosed from 2006 to 2015 at the Nippon Medical School Hospital were analyzed. Twelve patients were found to have plasmacytoid histology and diagnosed with PUC. Slides were evaluated for percentage of plasmacytoid variant, and stained for E-cadherin, N-cadherin, Vimentin, Fibronectin and Snail expression. RESULTS: The incidence of PUC was 1.9% (12/633). The median patient age at diagnosis was 71 years (range, 60-80 years) and the male-female ratio was 11:1. All but three patients had stage T2b or higher. The median overall survival was 10 months. In 10/12 cases, Snail and N-cadherin were positive. Vimentin was positive in 9/12 cases. Fibronectin was positive in 8/12 cases. While E-cadherin was negative in 10/12 cases. Nine cases showed > 10% plasmacytoid component. Eight of the nine patients (88.9%) with > 10% plasmacytoid component died. CONCLUSIONS: The results indicate that PUC may induce EMT and may be associated with high invasion.

DOI： 10.1186/s12894-020-00641-2

PubMed

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

The lipid cell variant of urethral carcinoma (UC) is rare and poorly understood clinicopathologically. A nodular tumor detected in the bladder of an 87-year-old man with asymptomatic gross hematuria was transurethrally resected, and high-grade UC, lipid cell variant, was diagnosed pathologically. The tumor cells resembled lipoblasts and contained numerous cytoplasmic vacuoles. Immunohistochemically, the tumor cells stained positive for the epithelial markers CK7, CK20, EMA, CAM5.2, and 34betaE12 and negative for vimentin and S100. Focal positivity for adipophilin was detected in cytoplasm but not in the vacuoles. These findings suggest that the patient had lipid-producing UC.

DOI： 10.1272/jnms.JNMS.2019_86-602

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

PURPOSE: Bladder endometriosis (BE) is rare. Deep invasive endometriosis is difficult to control with medications alone; such cases need surgical treatment. Good results of laparoscopic partial cystectomy with a transurethral (TU) resectoscope by the see-through technique for patients with BE are reported. MATERIALS AND METHODS: From January 2008 to February 2016, 12 cases of symptomatic BE were seen in our institution. The chief complaints of 9 cases were micturition pain during menstruation. Preoperative cystoscopy showed a bladder mass with blueberry spots. All surgeries were performed under general anesthesia. Laparoscopic surgery was performed with a fan of 4 ports in the lower abdomen. First, the uterus and bilateral ovaries were checked. Then, the TU resectoscope was inserted. When the affected bladder wall was identified, it was again observed with the laparoscopic light source off, which made it possible to observe the twilight leaking inside from the bladder. This twilight came from the light source of the TU resectoscope via the unaffected bladder wall. In contrast, the thickness of the affected wall prevented the light from inside the bladder from passing through it. We call this the "see-through technique." The tumor was then safely dissected with both laparoscopic and TU resection procedures. Finally, the bladder was sutured by laparoscopic procedures using absorbable sterile surgical suture. The urethral catheter was removed after cystography 7 days after the operation. RESULTS: The surgical margins of all cases were negative. There has been no recurrence of BE so far in any patients. There were no major adverse events perioperatively and the urinary symptoms improved in all cases. CONCLUSIONS: By laparoscopic partial cystectomy assisted with a TU resectoscope and see-through technique, the edge of BE could be easily and precisely identified. These procedures are effective and safe for BE surgical treatment.

DOI： 10.1159/000503795

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Deep learning algorithms have been successfully used in medical image classification. In the next stage, the technology of acquiring explainable knowledge from medical images is highly desired. Here we show that deep learning algorithm enables automated acquisition of explainable features from diagnostic annotation-free histopathology images. We compare the prediction accuracy of prostate cancer recurrence using our algorithm-generated features with that of diagnosis by expert pathologists using established criteria on 13,188 whole-mount pathology images consisting of over 86 billion image patches. Our method not only reveals findings established by humans but also features that have not been recognized, showing higher accuracy than human in prognostic prediction. Combining both our algorithm-generated features and human-established criteria predicts the recurrence more accurately than using either method alone. We confirm robustness of our method using external validation datasets including 2276 pathology images. This study opens up fields of machine learning analysis for discovering uncharted knowledge.

DOI： 10.1038/s41467-019-13647-8

Scopus

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Background: Various devices for isolating and detecting circulating tumor cells (CTCs) have been developed, whereas the CellSearch® system has been clinically used in numerous prostate CTC studies. CTCs might become more useful surrogate markers of prostate cancer, and they should be measured in all settings, but a smaller, low-cost CTC capture system is required. Methods: An inexpensive and highly sensitive microfluidic CTC-capture polymeric chip, developed by the Toyama Industrial Technology Center, as described in the following text, was used to assess the number of CTCs from patients with metastatic prostate cancer. After verifying that cultured human prostate cancer cells (PC3 and LNCaP) could be captured with the chip coated with anti-epithelial cell adhesion molecule (CD326) antibody, whole blood samples of 14 patients with prostate cancer were screened. Results: The average capture efficacy of PC3 cells was 94.60% in phosphate-buffered saline (PBS) and 83.82% in whole blood. The average capture efficacy of LNCaP cells was 82.73% in PBS and 75.78% in whole blood. CTCs were detected by the chip device in all 14 patients with metastatic prostate cancer using 2-mL blood samples. Although fewer CTCs were detected in patients with oligometastases, all patients with multiple distant metastases had CTCs. The average CTC count was 48 cells/mL (range 1-81 cells/mL). Conclusion: This CTC-chip will be able to capture CTCs and be useful to check CTCs as a surrogate marker in prostate cancer with smaller samples and lower cost in any small institution.

DOI： 10.1016/j.prnil.2019.01.003

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Deep learning algorithms have achieved great success in cancer image classification. However, it is imperative to understand the differences between the deep learning and human approaches. Using an explainable model, we aimed to compare the deep learning-focused regions of magnetic resonance (MR) images with cancerous locations identified by radiologists and pathologists. First, 307 prostate MR images were classified using a well-established deep neural network without locational information of cancers. Subsequently, we assessed whether the deep learning-focused regions overlapped the radiologist-identified targets. Furthermore, pathologists provided histopathological diagnoses on 896 pathological images, and we compared the deep learning-focused regions with the genuine cancer locations through 3D reconstruction of pathological images. The area under the curve (AUC) for MR images classification was sufficiently high (AUC = 0.90, 95% confidence interval 0.87-0.94). Deep learning-focused regions overlapped radiologist-identified targets by 70.5% and pathologist-identified cancer locations by 72.1%. Lymphocyte aggregation and dilated prostatic ducts were observed in non-cancerous regions focused by deep learning. Deep learning algorithms can achieve highly accurate image classification without necessarily identifying radiological targets or cancer locations. Deep learning may find clues that can help a clinical diagnosis even if the cancer is not visible.

DOI： 10.3390/biom9110673

Scopus

PubMed

researchmap

DOI： 10.1101/539791

researchmap

Other Link： http://orcid.org/0000-0003-0088-9324

Language：Japanese   Publishing type：Research paper (scientific journal)  

We describe a patient with thrombosis of the pampiniform plexus cured using heparin. A 40-year-old man was referred to our hospital with pain in the left scrotum. A physical examination revealed a painful, 20-mm long, beaded mass in the upper left paratesticular region. Magnetic resonance imaging and ultrasonography revealed 10-mm long thrombosis in the left pampiniform plexus, so intravenous heparin was started. The patient recovered well and was discharged on oral anticoagulation therapy after five days of hospitalization. The patient was completely asymptomatic, and ultrasonographic findings of the left testicle were normal at six months after starting treatment. We found 19 patients with thrombosis of the pampiniform plexus including the present patient, in the English and Japanese literature to date. Here, we review these 19 patients and discuss their clinical features.

DOI： 10.5980/jpnjurol.110.70

PubMed

J-GLOBAL

researchmap

DOI： 10.1200/JCO.2018.36.6_suppl.628

Web of Science

researchmap

DOI： 10.1200/JCO.2018.36.6_suppl.487

Web of Science

researchmap

DOI： 10.1200/JCO.2018.36.6_suppl.142

Web of Science

researchmap

Language：English   Publisher：(公社)日本医学放射線学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

A 73-year-old man presented with right lower back pain and dysuria. Right hydronephrosis and a large pelvic large mass were seen on computed tomography (CT). Although his prostate-specific antigen (PSA) was 0.5 ng/mL, an irregularly enlarged, stony, hard prostate was palpable on digital rectal examination. A prostate tumor was suspected, and a transrectal prostate biopsy and right transurethral ureteral stent placement were performed. Histological and immunohistochemical studies revealed diffuse large B-cell lymphoma. Positron emission tomography-computed tomography showed abnormal uptake in the stomach, cecum, right obturator lymph nodes, para-aortic lymph nodes, and dorsal left kidney. No abnormal findings were seen on bone marrow histology. Clinical stage IVA was confirmed according to Ann Arbor criteria. The patient achieved a complete response after 8 cycles of combination chemotherapy with rituximab, pirarubicin, cyclophosphamide, vincristine, and prednisolone.

DOI： 10.1272/jnms.JNMS.2018_85-37

PubMed

researchmap

Language：English   Publisher：(一社)日本核医学会  

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

IgG4-related kidney disease (IgG4-RKD) is a comprehensive term for renal lesions associated with IgG4-related disease (IgG4-RD), which is a recently recognized clinical entity characterized by a dense lymphoplasmacytic infiltrate rich in IgG4+ plasma cells with fibrosis affecting several organs. A 70-year-old woman was referred to our hospital for an abnormality at the left renal hilum detected by CT scan. Urinalysis was negative, urine cytology was rated as Class IIIa, and contrast-enhanced CT revealed left renal pelvic wall thickening without an irregular lumen and swelling of bilateral obturator lymph nodes. Ureterorenoscopy and biopsy were performed, and results showed no evidence of malignancy. Then, laparoscopic pelvic lymphadenectomy was performed. Plasma cells were the predominant infiltrating inflammatory cells; immunostaining showed marked infiltration of IgG4+ plasma cells with >10 IgG4+ plasma cells per high-power field, and the IgG4+/IgG+ cell ratio was over 40%. Serum IgG4 was extremely high. We made a final diagnosis of possible IgG4-related disease according to Comprehensive diagnostic Criteria for IgG4-related disease 2011. We report a long-term (40-month) follow-up case of IgG4-related kidney disease without therapy because there are no symptoms.

DOI： 10.5980/jpnjurol.108.229

PubMed

J-GLOBAL

researchmap

Language：Japanese   Publisher：日本医科大学医学会  

J-GLOBAL

researchmap

Language：English   Publisher：ELSEVIER SCIENCE INC  

DOI： 10.1016/j.juro.2014.02.851

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Partial nephrectomy is now the gold standard treatment for small renal tumors. Local recurrence is a major problem after partial nephrectomy, and local recurrence in the remnant kidney after partial nephrectomy is common. CASE PRESENTATION: A 77-year-old man underwent right partial nephrectomy for a T1 right renal cell carcinoma. Microscopic examination revealed a clear cell renal carcinoma, grade 2, stage pT3a. Although the surgical margin was negative, the carcinoma invaded the perirenal fat, and vascular involvement was strongly positive. Thirty months after partial nephrectomy, an enhanced computed tomographic scan showed local recurrence of the renal cell carcinoma extending into the inferior vena cava without renal mass. Hence, we performed right radical nephrectomy and intracaval thrombectomy. Microscopic examination revealed a clear cell carcinoma grade 2, stage pT3a + b. The patient is still alive with no evidence of recurrence 10 months post-procedure. CONCLUSION: To our knowledge, local recurrence of renal cell carcinoma extending into the inferior vena cava after partial nephrectomy has not been reported in the literature. Our case report emphasizes the importance of strict surveillance of patients after partial nephrectomy, especially for those with renal cell carcinoma positive for microvessel involvement.

DOI： 10.1186/1756-0500-7-198

PubMed

researchmap

DOI： 10.1007/s13691-013-0108-8

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：BRAZILIAN SOC UROL  

Neither computed tomography (CT) nor intravenous pyelography (IVP) alone can diagnose tumors of renal pelvic diverticula, but magnetic resonance urography (MRU) can obtain accurate preoperative information.

DOI： 10.1590/S1677-5538.IBJU.2014.02.19

Web of Science

PubMed

researchmap

researchmap

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)  

A 31-year-old man presented with edema in left lower leg and dyspnea. Computed tomographic scanning detected a right testicular tumor, multiple lung nodules, and inferior vena cava (IVC) thrombus. After insertion of an IVC filter, high inguinal orchiectomy was performed after the first combination chemotherapy. Pathological examination demonstrated an embryonal carcinoma with vascular invasion and direct tumoral extension into the right spermatic cord. According to our survey, this is the 14th case of testicular tumor with IVC thrombus in Japan.

Scopus

PubMed

J-GLOBAL

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

Language：Japanese   Publisher：(一社)腎癌研究会  

researchmap

Language：Japanese   Publisher：(一社)腎癌研究会  

researchmap

Language：Japanese   Publisher：(一社)腎癌研究会  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：日本外科系連合学会  

researchmap

Language：Japanese   Publisher：日本外科系連合学会  

researchmap

Language：English   Publisher：(一社)日本病理学会  

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(株)羊土社  

画像に含まれる情報は膨大である.特に科学的発見を進めていくためには,実際に目で見て観察し理解することの意義は大きい.定量化やその数理解析を通して画像を客観的な情報として扱うことができるAI技術は,生物・医学研究を行っていくうえで,今後もさらなる発展が期待される.一方で,複雑なデータ解析の背後を理解するためには,複数の分野における知識の統合が必要となる場面も多い.本稿では,これまでわれわれが行ってきた細胞組織像を用いたAI研究の中から,がんに対する発見的AIを用いた研究例と,生成AIの一つである超解像技術を電子顕微鏡像に応用した研究の方向性について紹介したい.(著者抄録)

researchmap

Language：Japanese   Publisher：日本外科系連合学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：日本外科系連合学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Other Link： https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J04260&link_issn=&doc_id=20230912340015&doc_link_id=10.1272%2Fmanms.19.283&url=https%3A%2F%2Fdoi.org%2F10.1272%2Fmanms.19.283&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：Japanese   Publisher：日本医科大学医学会  

researchmap

Other Link： https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J04260&link_issn=&doc_id=20230912340015&doc_link_id=10.1272%2Fmanms.19.283&url=https%3A%2F%2Fdoi.org%2F10.1272%2Fmanms.19.283&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

Language：Japanese   Publisher：(一社)腎癌研究会  

researchmap

Language：Japanese   Publisher：(一社)腎癌研究会  

researchmap

Language：Japanese   Publisher：(一社)腎癌研究会  

researchmap

Language：Japanese   Publisher：(一社)腎癌研究会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)腎癌研究会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本超音波医学会  

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Other Link： https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J00060&link_issn=&doc_id=20230124010005&doc_link_id=issn%3D0039-2359%26volume%3D284%26issue%3D3%26spage%3D201&url=http%3A%2F%2Fwww.pieronline.jp%2Fopenurl%3Fissn%3D0039-2359%26volume%3D284%26issue%3D3%26spage%3D201&type=PierOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00005_2.gif

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：日本医科大学医学会  

researchmap

Other Link： https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J04260&link_issn=&doc_id=20230208420013&doc_link_id=10.1272%2Fmanms.18.397&url=https%3A%2F%2Fdoi.org%2F10.1272%2Fmanms.18.397&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

Language：Japanese  

J-GLOBAL

researchmap

Other Link： https://search.jamas.or.jp/default/link?pub_year=2022&ichushi_jid=J04260&link_issn=&doc_id=20230208420013&doc_link_id=10.1272%2Fmanms.18.397&url=https%3A%2F%2Fdoi.org%2F10.1272%2Fmanms.18.397&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)腎癌研究会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)腎癌研究会  

researchmap

Language：Japanese   Publisher：(一社)腎癌研究会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)腎癌研究会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)腎癌研究会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：LIPPINCOTT WILLIAMS & WILKINS  

DOI： 10.1200/JCO.2022.40.6_suppl.453

Web of Science

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：LIPPINCOTT WILLIAMS & WILKINS  

DOI： 10.1200/JCO.2022.40.6_suppl.555

Web of Science

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：日本医科大学医学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J04260&link_issn=&doc_id=20210301380004&doc_link_id=10.1272%2Fmanms.17.21&url=https%3A%2F%2Fdoi.org%2F10.1272%2Fmanms.17.21&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J04260&link_issn=&doc_id=20210301380004&doc_link_id=%2Fcw1nimed%2F2021%2F001701%2F005%2F0021-0024%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcw1nimed%2F2021%2F001701%2F005%2F0021-0024%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：English   Publishing type：Research paper, summary (international conference)   Publisher：LIPPINCOTT WILLIAMS & WILKINS  

DOI： 10.1200/JCO.2021.39.6_suppl.473

Web of Science

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：日本医科大学医学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J04260&link_issn=&doc_id=20201204310019&doc_link_id=10.1272%2Fmanms.16.225&url=https%3A%2F%2Fdoi.org%2F10.1272%2Fmanms.16.225&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：日本医科大学医学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：日本医科大学医学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J04260&link_issn=&doc_id=20201204310027&doc_link_id=10.1272%2Fmanms.16.234&url=https%3A%2F%2Fdoi.org%2F10.1272%2Fmanms.16.234&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

Language：English   Publisher：(一社)日本核医学会  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：(公社)日本臨床細胞学会  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)西日本泌尿器科学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本核医学会  

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会  

症例は40歳の男性、左陰嚢部痛を主訴に当科を受診した。左精巣頭側の傍精巣領域に約20mm大の圧痛著明な数珠状に連なる腫瘤を認めた。急性陰嚢症の精査にて超音波検査、MRIおよびCTを施行した所、左蔓状静脈叢内腔に血栓像を認め、左蔓状静脈叢血栓症の診断にて抗凝固療法を施行した。その後、症状の消失及び画像所見での腫瘤消退を得た。われわれが集計し得た限りでは本疾患の報告は、自験例が19例目、本邦では2例目である。(著者抄録)

researchmap

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J01175&link_issn=&doc_id=20190205260014&doc_link_id=1390846609794446208&url=https%3A%2F%2Fcir.nii.ac.jp%2Fcrid%2F1390846609794446208&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_3.gif

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡・ロボティクス学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：腎癌研究会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：日本老年泌尿器科学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：日本老年泌尿器科学会  

J-GLOBAL

researchmap

Language：English  

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(株)日本臨床社  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会  

症例は70歳の女性。健診にて胸部異常陰影を指摘され近医受診。単純CTにて左腎洞部に腫瘤性病変を認め当科紹介となった。尿検査では異常を認めず、尿細胞診はclass IIIaであった。造影CTでは左腎盂壁肥厚と両側閉鎖リンパ節腫大を認めた。尿管鏡下にて左腎盂粘膜生検を施行したが異常所見は認めなかった。その後腹腔鏡下に閉鎖リンパ節生検を施行。摘出したリンパ節に著明なリンパ球および形質細胞浸潤を認め、免疫組織学的所見において、IgG4陽性細胞は10以上/HPF、IgG4/IgG陽性細胞比は40%以上であった。術後に測定した血中IgG4は662mg/dlと高値を示し、IgG4関連腎臓病診断基準に基づき、IgG4関連腎臓病と確定診断した。その後無症状で腎機能障害ないため無治療経過観察にて40ヵ月経過したが増悪所見を認めていない。(著者抄録)

researchmap

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2017&ichushi_jid=J01175&link_issn=&doc_id=20171109230011&doc_link_id=1390564238036815360&url=https%3A%2F%2Fcir.nii.ac.jp%2Fcrid%2F1390564238036815360&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_3.gif

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：Japanese  

J-GLOBAL

researchmap

Language：Japanese  

IgG4-related kidney disease (IgG4-RKD) is a comprehensive term for renal lesions associated with IgG4-related disease (IgG4-RD), which is a recently recognized clinical entity characterized by a dense lymphoplasmacytic infiltrate rich in IgG4+ plasma cells with fibrosis affecting several organs. A 70-year-old woman was referred to our hospital for an abnormality at the left renal hilum detected by CT scan. Urinalysis was negative, urine cytology was rated as Class IIIa, and contrast-enhanced CT revealed left renal pelvic wall thickening without an irregular lumen and swelling of bilateral obturator lymph nodes. Ureterorenoscopy and biopsy were performed, and results showed no evidence of malignancy. Then, laparoscopic pelvic lymphadenectomy was performed. Plasma cells were the predominant infiltrating inflammatory cells; immunostaining showed marked infiltration of IgG4+ plasma cells with >10 IgG4+ plasma cells per high-power field, and the IgG4+/IgG+ cell ratio was over 40%. Serum IgG4 was extremely high. We made a final diagnosis of possible IgG4-related disease according to Comprehensive diagnostic Criteria for IgG4-related disease 2011. We report a long-term (40-month) follow-up case of IgG4-related kidney disease without therapy because there are no symptoms.

DOI： 10.5980/jpnjurol.108.229

PubMed

J-GLOBAL

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本排尿機能学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本内視鏡外科学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器内視鏡学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：西日本泌尿器科学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(有)科学評論社  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：医学図書出版(株)  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局